Evidence map›Paper›PMID 28855433›Full record

ArticleJournal of atherosclerosis and thrombosis2018

Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome.

Fumiaki Furuyama, Shinji Koba, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Youichi Kobayashi

Open access · diamondAbstract read
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Effects of exercise on HDL functionality.Current opinion in lipidology · 2019
    Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Fumiaki FuruyamaDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Shinji KobaDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Yuya YokotaDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Fumiyoshi TsunodaDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Makoto ShojiDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Youichi KobayashiDivision of Cardiology, Department of Medicine, Showa University School of Medicine.
Showa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe evaluated whether exercised-based cardiac rehabilitation (CR) can ameliorate the HDL function, i.e., cholesterol efflux capacity (CEC) and paraoxonase-1 activity in patients with acute coronary syndrome (ACS).

methodsThis study is a retrospective analysis of stored serum from patients with ACS following successful percutaneous coronary intervention. The CEC, measured by a cell-based ex vivo assay using apolipoprotein B-depleted serum and

resultsApolipoprotein A-I (apoA-I) and CEC significantly increased by 4.0% and 9.4%, respectively, in the CR group, whereas HDL-cholesterol and AREA were not changed during the follow-up periods in both groups. Among CR patients, the CEC significantly increased, irrespective of the different statin treatment, while HDL-cholesterol and apoA-I significantly increased in patients treated with rosuvastatin or pitavastatin. Although CEC and AREA were significantly correlated each other, there is a discordance between CEC and AREA for their correlations with other biomarkers. Both CEC and AREA were significantly correlated with apoA-I rather than HDL-cholesterol. Changes in CEC and those in AREA were significantly correlated with those in apoA-I (rho=0.328, p=0.002, and rho=0.428, p<0.0001, respectively) greater than those in HDL-cholesterol (rho=0.312, p= 0.0042,and rho=0.343, p=0.003, respectively).

conclusionsCR can improve HDL function, and it is beneficial for secondary prevention.

Indexed as

Acute Coronary SyndromeAgedAnticholesteremic AgentsAryldialkylphosphataseBiomarkersCardiac RehabilitationCholesterol, HDLFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesAnticholesteremic AgentsAryldialkylphosphataseBiomarkersCholesterol, HDLPON1 protein, humanApolipoprotein A1Cardiac rehabilitationCholesterol efflux capacityHigh-density lipoproteinParaoxonase-1 activity

Identifiers

PMID28855433
PMCPMC5827085
OpenAlexW2753352394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.